Skip to content

Author

Turki Alfuhayr

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Drug repurposing for TAK1 inhibition in inflammatory diseases and cancer: virtual screening identifies nilotinib and dabrafenib as potential candidates.

TGF-beta-activated kinase 1 (TAK1) is a critical regulator of inflammatory and oncogenic signaling pathways and represents a promising therapeutic target for diseases ranging from chronic inflammation to cancer. However, existing therapies targeting downstream mediators often face limitations such as drug resistance an...

J. A. Alshehri, Turki Alfuhayr · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.